# Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

> **NCT06682195** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 35 (estimated)

## Conditions studied

- TNBC, Triple Negative Breast Cancer

## Interventions

- **DRUG:** Neoadjuvant chemotherapy combined with Toripalimab

## Key facts

- **NCT ID:** NCT06682195
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-09
- **Primary completion:** 2026-10-01
- **Final completion:** 2029-10-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06682195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06682195, "Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06682195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*